Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iC9/CD5CAR/IL-15 NK Cells for Aggressive T-cell Malignancies
NCT07137481Phase 2Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2027
- Primary completion
- Jul 2030
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of iC9/CD5CAR/IL-15 NK cells in T-cell lymphoma (PTCL), sponsored by University of Texas MD Anderson Cancer Center. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
iC9/CD5CAR/IL-15 NK cells
03
Conditions
T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07137481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07137481.